Utility of Cough Provocation Tests in Chronic Cough and Respiratory Diseases: A Comprehensive Review and Introduction of New Reference Ranges for the Capsaicin Test

Heikki Olavi Koskela, Hanna Maria Nurmi, Surinder Singh Birring

Unit for Medicine and Clinical Research, Pulmonary Division, Kuopio University Hospital, Kuopio, Finland
School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

ABSTRACT

Cough provocation tests (CPTs) are an objective measurement of the sensitivity of the cough reflex arc. However, they are not established in clinical practice because a large variability of response in healthy subjects limits their diagnostic value. There is a paucity of studies that have investigated CPT reference ranges in healthy subjects. This systematic review describes the variability of the responses to CPTs in healthy subjects and factors that influence it. A new analysis of 134 healthy subjects was conducted to create reference ranges for single-breath capsaicin CPT by calculating the interquartile ranges for the provocative concentration of capsaicin to induce 2 and 5 coughs. Female subjects had a more sensitive cough reflex than male counterparts. The ability of CPTs to distinguish various respiratory diseases from healthy subjects was also reviewed. Cough sensitivity was consistently heightened in the following groups: unselected patients with chronic, refractory, or recurrent cough, unexplained chronic cough, gastro-esophageal reflux-associated cough, cough-variant asthma, lower airway symptoms induced by chemical irritants, and fibrotic interstitial lung diseases. In the following groups, hypersensitivity of the cough reflex was present in those individuals whose symptom profile was predominated by cough: asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and sarcoidosis. In the following conditions, patients usually cough in order to expectorate mucus from their airways, not because of a hypersensitive cough reflex arc: productive cough, asthma, upper airway cough syndrome, COPD, bronchiectasis, cystic fibrosis, and chronic respiratory infections. CPTs have the potential to identify patients with chronic respiratory symptoms due to cough reflex hypersensitivity, thereby providing a targeted approach for therapy.

Keywords: Cough; reflex; hypersensitivity; capsaicin; citric acid; mannitol; saline solution, hypertonic solutions; reference values
INTRODUCTION

Most longstanding lower airway respiratory symptoms are probably associated with 1 or more of the following 3 pathophysiological phenomena: the increased tendency of the airway smooth muscle to constrict in response to environmental stimuli (airway hyperresponsiveness), the hypersensitivity of the cough reflex arc, and the increased mucus production. These 3 phenomena are probably independent, involving different mechanisms. Several studies have consistently shown that airway hyperresponsiveness does not correlate with cough reflex hypersensitivity. Furthermore, patients with cough due to increased mucus production usually do not show hypersensitivity of the cough reflex arc.

None of the 3 phenomena are specific for a single disorder and their relative importance probably varies among patients. Understanding the relative contribution of these phenomena in an individual patient would aid in targeting therapies of longstanding lower airway respiratory symptoms.

The tests to measure airway responsiveness, like the methacholine test, have been widely utilized in clinical patient management for decades. On the contrary, the tests to measure the sensitivity of the cough reflex arc, the cough provocation tests (CPTs), have not been established in clinical work. There are some obvious reasons for the unpopularity of the CPTs. First, numerous provocative agents with different mechanisms of action have been utilized. While it may be advantageous to utilize a tussive agent specific for a mechanism of action, the optimal tussive agent is not known in many situations. The cough response to capsaicin, citric acid, and tartaric acid involves the stimulation of the transient receptor potential vanilloid-1 (TRPV1) though the action of the acidic agents also involves other receptor types. The CPTs with hypertonic aerosols involve provocations with hypertonic saline, hypertonic histamine, mannitol, and hyperpnoea. These agents provoke cough without stimulating the TRPV1. In addition, water mist and adenosine have been utilized. Secondly, there are many methods to administer provocative agents, but they have not been standardized. Thirdly, the diluents of the provocative agents need to be prepared in specialized pharmacies and the reagents may be expensive and not universally available. Finally, a nebulizer is usually needed and this introduces several problems related to calibration, cleaning, and maintenance of the device. However, many of these shortcomings also apply to the tests that measure airway hyperresponsiveness, which have not hindered their widespread clinical use.

The most common reason for the limited clinical use of CPTs is that the responsiveness to these tests varies widely among healthy subjects, and therefore they cannot distinguish disease from normal healthy state. In the present article, we first review the evidence for the variability of the sensitivity to CPTs in healthy subjects. Then, we present a new analysis of previously presented material and suggest reference ranges for the single-breath capsaicin CPT. Finally, we review the ability of CPTs to distinguish healthy subjects from patients with various respiratory disorders. The present article does not cover studies investigating a reduced or hyposensitive cough reflex nor studies investigating the therapeutic use of the capsaicin challenge.
LITERATURE REVIEW FOR CPTs

A PubMed search was carried out with the following search terms: cough (with and without Medical Subject Headings definition) AND capsaicin/citric acid/tartaric acid/hypertonic saline/mannitol/hyperpnea/fog/water/adenosine/ATP. Utilizing the filters ‘English’ and ‘humans,’ the searches gave 1,143 articles published after the year 1980 up to February 19, 2021. The publications, in which CPTs were applied to a large number of healthy subjects or which included a comparison between healthy subjects and patients with respiratory diseases, were reviewed in detail.

From the publications including a large number of healthy subjects, the authors assessed the variability of the responses, the normality of the distribution of the responses, and the factors affecting the variability. In addition, the authors performed a re-analysis of a large group of healthy subjects previously presented by Prudon et al. in order to create reference ranges for the single-breath capsaicin CPT.

From the group comparison studies, the authors investigated whether there were statistically significantly different responses to CPTs (P < 0.05) between the healthy subjects and the patients. In addition, the following diagnostic performance indices were searched: the area under the receiver operating characteristic curve (aROC), the sensitivity, and the specificity. Whenever possible, the sensitivity and the specificity were calculated utilizing the cutoff value to give the largest Youden index (the sum of sensitivity and specificity). The level of distinction between groups was classified according to the aROC value of 0.7–0.8 indicating an acceptable, 0.8–0.9 an excellent, and more than 0.9 an outstanding distinction.

COUGH REFLEX SENSITIVITY IN HEALTHY SUBJECTS

Capsaicin is the most commonly utilized agent in CPTs. The capsaicin test is safe and has been performed in children as well as in adults. Some subjects report transient throat irritation. There are several studies applying single-breath, dosimetric capsaicin tests in large groups of healthy subjects. Prudon et al. investigated 134 healthy subjects in 2005. Among them, the geometric mean for the concentration of capsaicin that caused 2 coughs (C2) was 12.6 µmol/L (log SD, 0.5), and the concentration that caused 5 coughs (C5) was 158.5 µmol/L (log SD, 0.6). Another study involved 103 healthy adults with female predominance. After applying the anti-log function on the reported log-transformed values, the interquartile ranges were 1.91–15.8 µmol/l for the C2 and 7.76–251 µmol/L for the C5. Three studies reported neither the SDs nor interquartile ranges, but the means and the 99% or 95% confidence intervals. Of them, 2 involved adults with geometric mean C2 values of 11.0 and 32.3 µmol/L and C5 values of 64.6 and 151 µmol/L. A study in 100 healthy children reported the geometric mean C2 of 15.1 µmol/L and the geometric mean C5 of 64.2 µmol/L. In addition, there is one population of 96 healthy adults, presented in 2 publications, which only reported the median C5 value. It was more than the maximal concentration of 500 µmol/L, indicating that most subjects did not reach it.

Citric acid test was performed on 160 healthy subjects in order to create reference values to investigate a blunted cough response. However, the authors used a 15 seconds’ tidal breathing method via a face mask instead of the single-breath dosimetric method, which is the preferred method to investigate a hypersensitive cough reflex arc. In another study, tartaric
acid test was applied in 71 healthy subjects, but a tidal breathing method was utilized in that study as well. To the best of the authors' knowledge, there are no studies about the cough responses to hypo- or hypertonic aerosols or adenosine in large groups of healthy subjects.

The studies among healthy subjects as well as those among patients with respiratory disorders showed that females are more sensitive than male counterparts to a wide variety of cough-provoking agents, supporting separate reference ranges for both sexes. The cough sensitivity to capsaicin increases with age among healthy adults, whereas a converse relationship has been described in children. However, these associations were weak. Therefore, the reference ranges must not take the age into account. Atopy and smoking status do not seem to affect the cough sensitivity to capsaicin in healthy subjects.

Cough reflex sensitivity is a dynamic phenomenon. In healthy subjects, cough sensitivity to capsaicin increases significantly during upper respiratory infections and returns to the baseline levels at 4 weeks after the infection. Interestingly, the infections did not enhance airway responsiveness to methacholine. Furthermore, children with recurrent chronic cough but without airway hyperresponsiveness are more sensitive to capsaicin during the cough episode than during the cough-free period.

**CAPSAICIN REFERENCE RANGES: NEW ANALYSIS OF THE PREVIOUS PUBLICATION**

To the best of the authors' knowledge, a study presented by Prudent et al. is the largest one applying a single-breath, dosimetric capsaicin test in healthy subjects. The authors presented a very limited report of healthy subject data and we therefore conducted a more in-depth analysis to create reference ranges for capsaicin sensitivity.

There were 134 healthy subjects: 83 women, aged 19–78 years, and 51 men, aged 19–74 years. Exclusion criteria were a diagnosis of respiratory disease or current respiratory symptoms, GER, upper airways symptoms, and current smoking, or a history of smoking >10 pack-years. All healthy subjects had normal spirometric values, with 29% defined as being atopic. The subjects inhaled single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKo Digidoser; Pulmonary Data Services Instrumentation Inc., Louisville, CO, USA) at increasing concentrations from 0.49 to 500 µmol/L. The inspiratory flow was standardized at 0.5 L/sec with an inspiratory flow regulator valve, and the dosimeter output was set at 10 µL. The number of coughs was counted for 30 seconds after exposure to each dose. C2 and C5 were calculated by the linear interpolation of the log dose-response curves. A value of 500 µmol/L was assigned if interpolated values were >500 µmol/L. The repeatability of the results was good.

Even after the logarithmic conversion of C2 and C5, the distribution of the data differed significantly from normal distribution (Fig. 1). Therefore, instead of reporting SDs, we calculated the reference ranges as the 25–75 percentiles (the interquartile ranges) (Table 1). Female subjects were significantly more responsive to capsaicin than men and therefore, we calculated the reference ranges separately for the sex.

The study by Prudon et al. also involved 18 patients with unexplained chronic cough and 21 patients with cough-variant asthma (Figs. 2 and 3). Utilizing the reference values calculated...
among the healthy subjects, the sensitivity values were 76.5% and 81.0% for discriminating unexplained chronic cough and cough-variant asthma, respectively, from healthy subjects. The specificity for both was 75.3% each.

Table 2 includes the sensitivity and specificity values for the same data when the optimal cutoff values were determined by the Youden index. They

Fig. 1. The distribution of capsaicin concentrations to provoke 5 coughs (C5) among 134 healthy subjects presented by Prudon et al. Please note the logarithmic scale of the horizontal axis. The distribution of the C5 values differed significantly from the normal distribution even after 10-base logarithmic transformation (P < 0.001, one-sample Kolmogorov-Smirnov test). The subjects who did not cough more than 5 times even after the maximum capsaicin concentration were given a value of 500 µmol/L.

Table 1. The reference ranges for capsaicin provocative concentration to induce 2 coughs (C2) and 5 coughs (C5)

| The variable, sex, unit                  | 25%–75% percentage range (= the interquartile range) |
|-----------------------------------------|-----------------------------------------------------|
| C2, men, µmol/L                         | 7.63–35.9                                           |
| C2, women, µmol/L                       | 4.44–18.2                                           |
| C5, men, µmol/L                         | over 158                                             |
| C5, women, µmol/L                       | over 37.8                                           |

They are calculated from the results of 134 healthy subjects (51 men and 83 women) presented by Prudon et al. The upper limits could not be calculated for C5, since more than half of the healthy subjects did not cough five times even after the maximal capsaicin concentration of 500 µmol/L.

among the healthy subjects, the sensitivity values were 76.5% and 81.0% for discriminating unexplained chronic cough and cough-variant asthma, respectively, from healthy subjects. The specificity for both was 75.3% each. Table 2 includes the sensitivity and specificity values for the same data when the optimal cutoff values were determined by the Youden index. They

Fig. 2. The receiver operating characteristic (ROC) curve demonstrating the distinction between 21 patients with cough-variant asthma and 134 healthy subjects by the concentration of capsaicin to provoke 5 coughs (C5) in the study by Prudon et al. The area under the ROC curve is 0.850 indicating an excellent distinction.
showed just slightly better discrimination of these disease groups than those calculated by the new interquartile limits of the healthy subject reference ranges.

Cough Provocation Tests

COUGH REFLEX SENSITIVITY IN RESPIRATORY DISEASES AND COMPARISON WITH HEALTHY SUBJECTS

Unselected patients with chronic, refractory, and recurrent cough.

CPTs in patients who cough due to a wide range of associated disorders are discussed here. Chronic cough indicates a cough lasting for more than 8 weeks. Refractory cough indicates a cough that persists despite optimal treatment for the presumed background disorder. Recurrent cough indicates cough that tends to recur within a limited period.53 These patient groups have been consistently more sensitive than healthy subjects to a wide variety of cough provoking agents: capsaicin,20,29,35,40,44-46 citric acid,27,29,47 ATP,48 mannitol,42,47,49 and hypertonic saline.7 Some of these studies provide the sensitivity, specificity and aROC values (Table 2), and they suggest that the distinction from healthy subjects ranges from acceptable to outstanding.

Unexplained chronic cough

Unexplained chronic cough indicates a cough that has lasted for more than 8 weeks in which no diagnosable background disorder has been found.40 Compared to healthy subjects, patients with unexplained chronic cough are significantly more hypersensitive to capsaicin,1,30,50-54 mannitol,39 eucapnic voluntary hyperventilation,50 and hypertonic saline.50 The studies, from which the diagnostic performance indices were available, have shown an excellent distinction between unexplained chronic cough and healthy subjects (Table 2, Fig. 3).

Gastro-esophageal reflux-associated cough

These patients have been constantly and clearly more sensitive to capsaicin1,21,30,52,56 and citric acid7 than healthy subjects. The single study providing the diagnostic indices showed an excellent distinction between these patients and healthy subjects by the capsaicin test (Table 2).

Fig. 3. The concentration of capsaicin to provoke 5 coughs (C5) in 134 healthy subjects and in 18 subjects with unexplained chronic cough, which were presented by Prudon et al.30 The lower boundary of the box indicates 25th percentile, a line within the box marks the median, and the higher boundary indicates the 75th percentile. The error bars above and below the boxes indicate the 90th and 10th percentiles. P < 0.001 between the groups (Mann-Whitney U test).
Table 2. The ability of cough provocation tests to distinguish various groups of patients from healthy subjects

| Study (year)          | Agent        | Cut-off value | Type of patients with cough | Cough patients | Sensitivity | Healthy subjects | Specificity | Youden index | aROC  |
|----------------------|--------------|---------------|-----------------------------|----------------|-------------|------------------|-------------|--------------|-------|
| Singapuri et al. (2008) | Mannitol     | ≤ 550 mg to provoke 5 coughs | Unselected chronic cough   | 13             | 62%         | 16               | 83%         | 143          | NA    |
| Koskela et al. (2018)  | Mannitol     | ≥ 12.0 coughs/100 mg | Unselected chronic cough   | 17             | 82%         | 15               | 100%        | 182          | 0.949 |
| Nurmi et al. (2019)   | Mannitol     | ≥ 5.35 coughs/100 mg | Unselected chronic cough   | 36             | 92%         | 25               | 64%         | 156          | 0.847 |
| Nurmi et al. (2019)   | Citric acid  | < 281 mmol/L to provoke 5 coughs | Unselected chronic cough   | 36             | 88%         | 25               | 67%         | 155          | 0.763 |
| Koskela et al. (2008) | Hypertonic saline | ≥ 2,213 mOsm/kg to provoke 15 coughs | Unselected chronic cough   | 47             | 66%         | 19               | 84%         | 150          | 0.775 |
| O’Connell et al. (1995) | Capsaicin   | < 31.6 µmol/L to provoke 5 coughs | Unexplained chronic cough  | 16             | 94%         | 8                | 100%        | 194          | NA    |
| Prudon et al. (2005)  | Capsaicin    | < 0.005 µmol/L to provoke 2 coughs | Unexplained chronic cough  | 18             | 83%         | 134              | 80%         | 163          | 0.867 |
| Prudon et al. (2005)  | Capsaicin    | < 29.2 µmol/L to provoke 5 coughs | Unexplained chronic cough  | 18             | 72%         | 134              | 88%         | 160          | 0.853 |
| Johansson et al. (2018) | Mannitol     | ≥ 69 coughs during the whole test | Unexplained chronic cough  | 22             | 95%         | 21               | 90%         | 185          | NA    |
| Johansson et al. (2008) | Hypertonic saline | ≥ 11 coughs during the whole test | Unexplained chronic cough  | 21             | 95%         | 21               | 95%         | 190          | NA    |
| Johansson et al. (2018) | Dry air hyperpnoea | ≥ 14 coughs during the whole test | Unexplained chronic cough  | 23             | 95%         | 21               | 86%         | 181          | NA    |
| Nieto et al. (2003)   | Capsaicin    | < 15 µmol/L to provoke 5 coughs | Gastroesophageal reflux-associated cough | 23             | 98%         | 86               | 66%         | 164          | 0.880 |
| Koskela et al. (2004) | Mannitol     | ≥ 4.0 coughs/100 mg | Asthma                      | 37             | 86%         | 10               | 90%         | 186          | 0.930 |
| Nurmi et al. (2019)   | Mannitol     | ≥ 17.2 coughs/100 mg | Asthma                      | 11             | 91%         | 25               | 92%         | 183          | 0.956 |
| Johansson et al. (2018) | Mannitol     | ≥ 48 coughs during the whole test | Asthma                      | 16             | 80%         | 21               | 76%         | 156          | NA    |
| Koskela et al. (2008) | Hypertonic saline | ≥ 1.428 mOsm/kg to provoke 15 coughs | Asthma                      | 26             | 62%         | 19               | 100%        | 162          | 0.828 |
| Purokivi et al. (2011) | Hypertonic saline | ≥ 0.0005 mOsm/kg | Asthma                      | 36             | 89%         | 14               | 93%         | 182          | 0.935 |
| Johansson et al. (2018) | Hypertonic saline | ≥ 5 coughs during the whole test | Asthma                      | 16             | 100%        | 21               | 87%         | 181          | NA    |
| Koskela et al. (2005) | Hypertonic histamine | ≥ 12.2 coughs/mg/mL | Asthma                      | 32             | 62%         | 15               | 93%         | 155          | 0.830 |
| Purokivi et al. (2008) | Hypertonic histamine | ≥ 69.2 coughs/mg/mL | Asthma                      | 30             | 80%         | 25               | 96%         | 176          | NA    |
| Purokivi et al. (2008) | Dry air hyperpnoea | ≥ 0.095 µmol/L to 5 coughs | Asthma                      | 37             | 65%         | 14               | 100%        | 180          | 0.911 |
| Johansson et al. (2005) | Hypertonic saline | ≥ 2.213 µmol/L to provoke 5 coughs | Asthma                      | 41             | 81%         | 134              | 80%         | 161          | 0.833 |
| Prudon et al. (2005)  | Capsaicin    | < 4.94 µmol/L to provoke 2 coughs | Cough-variant asthma        | 21             | 81%         | 134              | 80%         | 161          | 0.850 |
| Prudon et al. (2005)  | Capsaicin    | < 42.1 µmol/L to provoke 5 coughs | Cough-variant asthma        | 21             | 81%         | 134              | 80%         | 161          | 0.850 |
| Pullerits et al. (2014) | Capsaicin | < 15.6 µmol/L to provoke 5 coughs | Chemical sensitive patients | 46             | 96%         | 29               | 86%         | 182          | 0.972 |
| Ternesten-Hasséus et al. (2006) | Capsaicin, tidal breathing | Not defined | Chemical sensitive patients | 15             | 80%         | 15               | 100%        | 180          | 0.950 |
| Ternesten-Hasséus et al. (2006) | Capsaicin, total breathing | Not defined | Chemical sensitive patients | 15             | 80%         | 15               | 87%         | 167          | 0.900 |
| Doherty et al. (2010) | Capsaicin | < 31.25 µmol/L to provoke 5 coughs | Idiopathic pulmonary fibrosis | 15             | 87%         | 96               | 90%         | 177          | NA    |
| Hope-Gill et al. (2003) | Capsaicin | > 2 µmol/L to provoke 2 coughs | Idiopathic pulmonary fibrosis | 10             | 70%         | 10               | 100%        | 170          | NA    |

The table includes studies in which the authors had the access to the original data, studies that report the diagnostic performance indices, and studies in which these indices can be reliably estimated utilizing the published tables or the figures. The cutoff values are those giving the largest sum of sensitivity and the specificity (Youden index).

*Estimated from the Fig. 1 of the publication, †re-calculated from the original data, ‡estimated from the Fig. 4 of the publication, §estimated from the Fig. 1 of the publication, †estimated from the Fig. 18 of the publication.
Asthma

In the majority of studies, patients with stable asthma do not differ from healthy subjects with respect to cough sensitivity to capsaicin,\textsuperscript{1,4,5,7,19,29,30,35,45,52,53,58-60} citric acid,\textsuperscript{16,19} and tartaric acid.\textsuperscript{12,14} However, there are also some studies demonstrating a statistically significant difference between the two groups utilizing capsaicin\textsuperscript{18,21,61,62} or citric acid.\textsuperscript{29} A recent study reported a lower capsaicin C2, but not C5, in asthmatic children than in the control subjects.\textsuperscript{36} The capsaicin sensitivity in asthma may be associated with the subjective cough severity\textsuperscript{63} and poor asthma control.\textsuperscript{63} It is possible that the distinction between healthy and asthmatic subjects is better if maximum cough responses are used instead of threshold values to describe the cough responsiveness.\textsuperscript{62} However, in one study, the capsaicin sensitivity did not differ between the 2 groups even utilizing the maximum responses.\textsuperscript{53} The conflicting results may be partially explained by the finding that patients with allergic asthma are more sensitive to capsaicin during the pollen season than out of the season.\textsuperscript{64} On the contrary to CPTs with capsaicin and acidic aerosols, the cough responsiveness to hypertonic CPTs has been found to be consistently enhanced in asthma and the distinction from healthy subjects has been from excellent to outstanding (Table 2, Fig. 4).\textsuperscript{7,55,65-68} The cough responsiveness to hypertonic saline and dry air hyperpnea are associated with impaired cough-related quality of life in asthma.\textsuperscript{69}

Cough-variant asthma

In concordance with a study showing that subjective cough severity is associated with cough responsiveness to capsaicin in classic asthma,\textsuperscript{18} the subjects with cough-variant asthma are consistently shown to be more sensitive to capsaicin than healthy subjects.\textsuperscript{1,30,59,70} The material presented by Prudon et al.\textsuperscript{30} shows that the distinction between cough-variant asthma and healthy subjects by the capsaicin test is excellent (Table 2, Fig. 2).

Patients with lower airway symptoms induced by chemical irritants

A special subgroup of patients with lower airway symptoms induced by chemical irritants like solvents and perfumes has been shown to be especially hypersensitive to capsaicin demonstrating an outstanding distinction from normal subjects (Table 2)\textsuperscript{5,30,71-78} However, the

---

**Fig. 4.** The cumulative number of coughs in relation to minute ventilation evoked by isocapnic hyperpnea of dry air challenge in 10 healthy (A) and 30 asthmatic (B) subjects. The horizontal lines at or below zero indicate subjects who did not cough at all. Reproduced from reference\textsuperscript{66} with permission.
results of some of these studies must be interpreted with caution as the patients have been selected on the basis of a previous positive capsaicin test result.\(^71,74,75\)

**Obstructive sleep apnea syndrome**
Obstructive sleep apnea syndrome may cause chronic cough.\(^79\) According to one study, the patients suffering from this syndrome are more sensitive to capsaicin than healthy subjects and subjects with simple snoring.\(^80\) More studies are needed to confirm this.

**Interstitial lung diseases (ILDs)**
A small group of unselected patients with ILD showed similar cough sensitivity to capsaicin when compared to healthy subjects.\(^1\) On the contrary, patients with idiopathic pulmonary fibrosis\(^30,37,81\) and with systemic sclerosis-associated ILD\(^46\) have shown to be clearly more sensitive to capsaicin than healthy subjects are (Table 2). Of note, patients with systemic sclerosis but without ILD did not differ from healthy subjects in this respect. These results suggest that in ILDs, the heightened cough reflex sensitivity is associated with the degree of lung parenchymal fibrosis.

**Sarcoidosis**
The studies on patients with sarcoidosis are conflicting. A study by Prudon *et al.*\(^30\) included 13 sarcoidosis patients with mild or absent cough; their capsaicin sensitivity did not differ from that of 134 healthy subjects. The largest group of sarcoidosis patients was investigated by Sinha *et al.*\(^23\) They compared 32 patients with pulmonary sarcoidosis and 40 age- and sex-matched healthy controls. The former subjects were significantly more sensitive to capsaicin, although the overlap was large. Among the patients with sarcoidosis, the capsaicin sensitivity was the only factor that was associated with the objectively measured 24-hour cough counts in multivariate analysis that included also lung function parameters, chest radiograph findings, serum angiotensin-converting enzyme level, and smoking status.

**Upper airway cough syndrome (UACS) including postnasal drip syndrome and chronic rhinosinusitis-associated cough**
The studies on patients with UACS are conflicting. In some studies, these patients have shown a greater sensitivity to capsaicin when compared to healthy subjects.\(^32,82,83\) However, there are also studies suggesting that these patients’ sensitivity to capsaicin is not enhanced.\(^1,21,58,70\) Among the 4 negative studies, 3 included only small groups of UACS patients (n = 11–13), but 1 negative study by Cho *et al.*\(^70\) included 33 patients, thus decreasing the possibility of the type II statistical error. The authors of that study suggested that chronic cough in postnasal drip associated with sinusitis may be caused by mechanical irritations of cough receptors with normal sensitivity.\(^70\) Furthermore, the conflicting results may be partially explained by the finding that patients with allergic rhinitis are more sensitive to capsaicin during the pollen season than out of the season.\(^82\) Among the UACS patients with documented cough hypersensitivity, laryngopharyngeal anesthesia only slightly decreased the responsiveness to inhaled capsaicin, suggesting a major role for lower airway sensory nerves or central sensitizing.\(^83\)

**Chronic obstructive pulmonary disease (COPD)**
The studies on patients with COPD are conflicting. In one study, patients with COPD and healthy subjects were challenged to capsaicin and citric acid. The patients with COPD were hypersensitive to capsaicin but not to citric acid.\(^29\) In another study, patients with COPD were hypersensitive to citric acid, but not to capsaicin.\(^84\) One negative study utilizing
capsaicin may have been too small (n = 8) to reveal a statistically significant difference. A large capsaicin study with 56 COPD patients and 96 healthy subjects demonstrated a clear distinction between the 2 groups. Among the COPD patients, there was a significant association between the subjective cough severity and capsaicin sensitivity.

**Bronchiectasis and cystic fibrosis**

The studies on patients with bronchiectasis are conflicting. In one study involving 7 stable bronchiectasis patients and another involving 5 stable patients, the cough sensitivity to capsaicin did not differ from that of healthy subjects. However, the former study also included 5 bronchiectasis patients with acute respiratory infection and they were hypersensitive to capsaicin. A study by Prudon et al. involved 5 patients with bronchiectasis and their capsaicin sensitivity was higher than that of healthy subjects. The largest group was presented by Torrego et al. That study included 22 patients with bronchiectasis and 20 healthy controls matched for age and sex. Patients with bronchiectasis had increased sensitivity to capsaicin compared to controls (P < 0.03), but the overlap was large. Capsaicin sensitivity correlated with impaired cough-related quality of life and with the total cough symptom score. Bronchiectasis is often associated with cystic fibrosis. In children with cystic fibrosis, the capsaicin C2 was higher than that in healthy subjects, indicating blunted cough sensitivity, but once these patients started coughing, they coughed multiple times.

**Productive cough**

In general, patients with chronic, productive cough do not differ from healthy subjects with respect to capsaicin sensitivity, whereas those with chronic, dry cough do. Interestingly, this seems to apply to acute cough as well. In a prospective study with 103 healthy volunteers, capsaicin sensitivity increased during upper respiratory tract infection only among subjects with dry cough during the infection, but not in those with productive cough during the infection. These findings suggest that cough can occur in association with either excess mucus production leading to productive cough or an increase in the sensitivity if the cough reflex arc, leading to non-productive cough.

**CLINICAL IMPLICATIONS OF CPTs**

This review shows that although the responsiveness to CPTs is widely distributed among healthy subjects, these tests can effectively distinguish certain patient groups from healthy subjects. Therefore, they could be useful not only in research, but also in everyday clinical practice. For this purpose, reference ranges are obligatory. This article for the first time presents reference ranges for the single-breath capsaicin CPT. Usually, the reference ranges are calculated as mean ± 1.96 SD in a healthy population. However, the C2 and C5 values were not normally distributed even after logarithmic conversion among the healthy population investigated by Prudon et al. Therefore, we calculated the reference ranges as interquartile ranges. Utilizing the interquartile ranges, the sensitivity and specificity values for unexplained chronic cough and cough-variant asthma were almost as high as those utilizing the optimal cutoff values determined by the Youden index. Thus, a value below these interquartile ranges indicates that cough reflex arc hypersensitivity may explain the patient’s respiratory symptoms. The reproducibility of C5 is reported to be superior to that of C2, suggesting that C5 is the preferred end-point when investigating a hypersensitive cough.

---

https://e-aair.org  https://doi.org/10.4168/aair.2021.13.6.833
Cough Provocation Tests

reflex. C2 may be suitable to investigate a hyposensitive cough reflex since the upper limit of its reference range could be determined in the present analyses.

Though the healthy subjects’ capsaicin C2 and C5 values in other studies\textsuperscript{1,3,18,21,35,37} fit rather well in the interquartile ranges now presented, the present reference ranges can only be applied to results obtained by the exactly the same test protocol and equipment as used by Prudon \textit{et al.}\textsuperscript{30} Lack of standardization of the CPT protocols is one of the greatest hinders for their use in clinical practice.\textsuperscript{23} At the moment, the mannitol test is the only CPT, which is standardized.\textsuperscript{26} Unfortunately, there is no data to calculate reference ranges for the cough responsiveness to mannitol or any other cough provocation agents than capsaicin. Also, the reference ranges for the maximal cough response to capsaicin are lacking.

The present review shows that CPTs can effectively distinguish healthy subjects from unselected patients with chronic, refractory, or recurrent cough, patients with unexplained (idiopathic) chronic cough, gastro-esophageal reflux-associated cough, cough-variant asthma, lower airway symptoms induced by chemical irritants, and fibrotic ILDs. In these disorders, hypersensitivity of the cough reflex arc seems to be a rather uniform phenomenon. In a clinical setting, high cough sensitivity to capsaicin or citric acid in a patient with chronic respiratory symptoms suggests that these disorders should be on the top of the list of possible background disorders.

The review also identified disorders, in which an enhanced sensitivity of the cough reflex arc is not a general feature, but is likely to be present only in those individuals with cough being a predominate feature. These disorders include asthma, COPD, bronchiectasis, and sarcoidosis. In a clinical setting, performing a CPT might be useful in these patients to identify the presence of cough reflex hypersensitivity and potentially alter clinical management. Furthermore, the review also identified disorders in which the timing of the test may be important: in allergic asthma and in allergic rhinitis, cough hypersensitivity may be present during the pollen season, but vanish outside it.\textsuperscript{64,82} The patients with asthma is a special group with hypersensitivity to hyperosmolar aerosols, but in general, normal responses to capsaicin and acidic agents. The possible reasons for this discrepancy have been discussed in detail elsewhere.\textsuperscript{26} In a clinical setting, high cough sensitivity to hypertonic aerosols may suggest asthma as the most probable cough background disorder.

However, it is important to recognize that not all patients who suffer from chronic cough demonstrate heightened sensitivity of the cough reflex arc. It is probable that many patients with productive cough, asthma, UACS, COPD, bronchiectasis, and cystic fibrosis cough in order to expectorate mucus from their airways, not because of a hypersensitive cough reflex arc.\textsuperscript{1,3,70} This is probably also the case in chronic respiratory infections, although there are no studies utilizing CPTs in them.\textsuperscript{87} In such patients, clinical management should focus on clearing the excessive mucus production. Furthermore, some patients with asthma and cough-variant asthma probably cough due to bronchoconstriction\textsuperscript{18,30} and among them, the clinical management should focus on bronchodilation. However, in some of these patients, cough reflex hypersensitivity may be responsible for their respiratory symptoms. Therefore, performing a CPT in a clinical setting could aid in directing the management of these patients as well. Finally, it should be noted that many of the referred studies included rather small number of patients raising the possibility of the type 2 statistical error.
CONCLUSIONS

Despite the wide variability of the cough sensitivity in healthy subjects, CPTs can distinguish certain chronic cough patients from healthy subjects. This article for the first time presents reference ranges for a dosimetric, single-breath capsaicin test. They are based on the material by Prudon et al. and can be applied only on results obtained by their protocol. The CPTs should be standardized. Not all patients, who suffer from chronic cough, have an abnormally functioning cough reflex arc. CPTs can help clarify whether an individual patient’s chronic respiratory symptoms may be due to cough reflex arc hypersensitivity, thereby helping direct the management of the symptoms. This is especially important now, since new medications are emerging which are capable of reducing the sensitivity of the cough reflex arc.

ACKNOWLEDGMENTS

The authors thank Eva Millqvist for providing the original data of their studies.

REFERENCES

1. Choudry NB, Fuller RW. Sensitivity of the cough reflex in patients with chronic cough. Eur Respir J 1992;5:296-300. PUBMED
2. Fujimura M, Kamio Y, Hashimoto T, Matsuda T. Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy. J Asthma 1994;31:463-72. PUBMED | CROSSREF
3. O’Connell F, Thomas VE, Studham JM, Pride NB, Fuller RW. Capsaicin cough sensitivity increases during upper respiratory infection. Respir Med 1996;90:279-86. PUBMED | CROSSREF
4. Chang AB, Phelan PD, Sawyer SM, Robertson CF. Airway hyperresponsiveness and cough-receptor sensitivity in children with recurrent cough. Am J Respir Crit Care Med 1997;155:1985-9. PUBMED | CROSSREF
5. Millqvist E, Bende M, Löwhagen O. Sensory hyperreactivity–a possible mechanism underlying cough and asthma-like symptoms. Allergy 1998;53:1208-12. PUBMED | CROSSREF
6. Park HW, Kim SH, Chang VS, Lee BJ, Min KU, Kim YY, et al. Complementary roles of capsaicin cough sensitivity test and induced sputum test to methacholine bronchial provocation test in predicting response to inhaled corticosteroids in patients with chronic nonproductive cough. Ann Allergy Asthma Immunol 2007;98:533-9. PUBMED | CROSSREF
7. Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, Tukiainen HO. Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 2008;38:1100-7. PUBMED | CROSSREF
8. Sheppard D, Rizk NW, Boushey HA, Bethel RA. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis 1983;127:691-4. PUBMED
9. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984;129:211-5. PUBMED
10. Choudry NB, Fuller RW, Anderson N, Karlsson JA. Separation of cough and reflex bronchoconstriction by inhaled local anaesthetics. Eur Respir J 1990;3:579-83. PUBMED
11. Smith CA, Adamson DL, Choudry NB, Fuller RW. The effect of altering airway tone on the sensitivity of the cough reflex in normal volunteers. Eur Respir J 1991;4:1078-9. PubMed

12. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Cough receptor sensitivity and bronchial responsiveness in normal and asthmatic subjects. Eur Respir J 1992;5:291-5. PubMed

13. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effects of methacholine induced bronchoconstriction and procaterol induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid. Thorax 1992;47:441-5. PubMed | Crossref

14. Fujimura M, Sakamoto S, Kamio Y, Saito M, Miyake Y, Yasui M, et al. Cough threshold to inhaled tartaric acid and bronchial responsiveness to methacholine in patients with asthma and sino-bronchial syndrome. Intern Med 1992;31:17-21. PubMed | Crossref

15. Hathaway TJ, Higenbottam TW, Morrison JF, Clelland CA, Wallwork J. Effects of inhaled capsaicin in heart-lung transplant patients and asthmatic subjects. Am Rev Respir Dis 1993;148:1233-7. PubMed | Crossref

16. Schmidt D, Jöress RA, Magnussen H. Citric acid-induced cough thresholds in normal subjects, patients with bronchial asthma, and smokers. Eur J Med Res 1997;2:384-8. PubMed

17. Fujimura M, Kamio Y, Hashimoto T, Matsuda T. Airway cough sensitivity to inhaled capsaicin and bronchial responsiveness to methacholine in asthmatic and bronchitic subjects. Respiriology 1998;3:267-72. PubMed | Crossref

18. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax 2000;55:643-9. PubMed | Crossref

19. Di Franco A, Dente FL, Giannini D, Vagaggini B, Conti I, Macchioni P, et al. Effects of inhaled corticosteroids on cough threshold in patients with bronchial asthma. Pulm Pharmacol Ther 2001;14:35-40. PubMed | Crossref

20. Ternesten-Hasséus E, Farbrot A, Löwhagen O, Millqvist E. Sensitivity to methacholine and capsaicin in patients with unclear respiratory symptoms. Allergy 2002;57:501-7. PubMed | Crossref

21. Nieto L, de Diego A, Perpiñá M, Compte L, Garrigues V, Martinez E, et al. Cough reflex testing with inhaled capsaicin in the study of chronic cough. Respir Med 2003;97:393-400. PubMed | Crossref

22. Koskela HO, Martens R, Brannan JD, Anderson SD, Leuppi J, Chan HK. Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects. Respirology 2005;10:442-8. PubMed | Crossref

23. Sinha A, Lee KK, Rafferty GF, Yousaf N, Pavord ID, Galloway J, et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J 2016;47:1461-71. PubMed | Crossref

24. Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, et al. ERS guidelines on the assessment of cough. Eur Respir J 2007;29:1256-76. PubMed | Crossref

25. Wallace E, Guiu Hernandez E, Ang A, Hiew S, Macrae P. A systematic review of methods of citric acid cough reflex testing. Pulm Pharmacol Ther 2019;58:101827. PubMed | Crossref

26. Koskela HO, Nurmi HM, Purokivi MK. Cough-provocation tests with hypertonic aerosols. ERJ Open Res 2020;6:338. PubMed | Crossref

27. Rai ZL, Fowles HE, Wright C, Howard J, Morice AH. The effect of pH on citric acid cough challenge: a randomised control trial in chronic cough and healthy volunteers. Respir Physiol Neurobiol 2018;257:51-4. PubMed | Crossref

28. Laloo UG, Fox AJ, Belvisi MG, Chung KF, Barnes PJ. Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol (1985) 1995;79:1082-7. PubMed | Crossref

29. Belvisi MG, Birrell MA, Khalid S, Wortley MA, Dockry R, Coote J, et al. Neurophenotypes in airway diseases. insights from translational cough studies. Am J Respir Crit Care Med 2016;193:1364-72. PubMed | Crossref
30. Prudon B, Birring SS, Varad DD, Hall AP, Thompson JP, Pavord ID. Cough and glottic-stop reflex sensitivity in health and disease. Chest 2005;127:550-7.

31. Cho PS, Fletcher HV, Turner RD, Jolley CJ, Birring SS. Impaired cough suppression in chronic refractory cough. Eur Respir J 2019;53:1802203.

32. Mandrekar RN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010;5:1315-6.

33. Dicpinigaitis PV, Alva RV. Safety of capsaicin cough challenge testing. Chest 2005;128:196-202.

34. Wang R, Fowler SI, Niven R, Ryan D, Holt K, Mitchell J, et al. Investigating the safety of capsaicin cough challenge in severe asthma. Clin Exp Allergy 2019;49:932-4.

35. Chang AB, Phelan PD, Sawyer SM, Del Brocco S, Robertson CE. Cough sensitivity in children with asthma, recurrent cough, and cystic fibrosis. Arch Dis Child 1997;77:331-4.

36. Kunc P, Fabry J, Lucanska M, Zatko T, Grendar M, Pecova R. Cough reflex sensitivity in asthmatic children. Physiol Res 2020;69 Suppl 1:S147-50.

37. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000;55:1028-32.

38. Monroe MD, Manco K, Bennett R, Huckabee M. Citric acid cough reflex test: Establishing normative data. Lang Hear 2014;17:216-24.

39. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Sex difference in the inhaled tartaric acid cough threshold in non-atopic healthy subjects. Thorax 1990;45:633-4.

40. Lai K, Long L, Yi F, Tang J, Chen Z, Chen F, et al. Age and sex distribution of chinese chronic cough patients and their relationship with capsaicin cough sensitivity. Allergy Asthma Immunol Res 2019;11:871-84.

41. Kastelik JA, Thompson RH, Aziz I, Ojoo JC, Redington AE, Morice AH. Sex-related differences in cough reflex sensitivity in patients with chronic cough. Am J Respir Crit Care Med 2002;166:961-4.

42. Koskela HO, Lake C, Wong K, Brannan JD. Cough sensitivity to mannitol inhalation challenge identifies subjects with chronic cough. Eur Respir J 2018;51:1800294.

43. McGarvey L, Gibson PG. What is chronic cough? Terminology. J Allergy Clin Immunol Pract 2019;7:1711-4.

44. Birring SS, Matos S, Patel RB, Prudon B, Evans DH, Pavord ID. Cough frequency, cough sensitivity and health status in patients with chronic cough. Respir Med 2006;100:1105-9.

45. Niimi A, Torrego A, Nicholson AG, Cosio BG, Oates TB, Chung KF. Nature of airway inflammation and remodeling in chronic cough. J Allergy Clin Immunol 2005;116:565-70.

46. Laloo UG, Lim S, DuBois R, Barnes PJ, Chung KF. Increased sensitivity of the cough reflex in progressive systemic sclerosis patients with interstitial lung disease. Eur Respir J 1998;11:702-5.

47. Nurmi HM, Lätti AM, Brannan JD, Koskela HO. Comparison of mannitol and citric acid cough provocation tests. Respir Med 2019;158:14-20.

48. Fowles HE, Rowland T, Wright C, Morice A. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J 2017;49:1601452.

49. Singapuri A, McKenna S, Brightling CE. The utility of the mannitol challenge in the assessment of chronic cough: a pilot study. Cough 2008;4:10.
50. Johansson EL, Gustafsson P, Millqvist E, Ternesten-Hasséus E. Small and large airways’ reactions to inhaled capsaicin in patients with chronic idiopathic cough, or asthma and in healthy control subjects. Exp Lung Res 2019;45:55-64. PUBMED | CROSSREF

51. O’Connell F, Springall DR, Moradoghi-Haftvani A, Krausz T, Price D, Fuller RW, et al. Abnormal intraepithelial airway nerves in persistent unexplained cough? Am J Respir Crit Care Med 1995;152:2068-75. PUBMED | CROSSREF

52. Niimi A, Nguyen LT, Usmani O, Mann B, Chung KF. Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax 2004;59:608-12. PUBMED | CROSSREF

53. Hilton EC, Baverel PG, Woodcock A, Van Der Graaf PH, Smith JA. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the CS end point. J Allergy Clin Immunol 2013;132:847-855.e1. PUBMED | CROSSREF

54. Long L, Yao H, Tian J, Luo W, Yu X, Yi F, et al. Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respir Res 2019;20:112. PUBMED | CROSSREF

55. Johansson EL, Ternesten-Hasséus E, Gustafsson P, Pullerits T, Arvidsson M, Millqvist E. Small and large airway reactions to osmotic stimuli in asthma and chronic idiopathic cough. Pulm Pharmacol Ther 2018;49:112-8. PUBMED | CROSSREF

56. Qiu Z, Yu L, Xu S, Liu B, Zhao T, Lú H, et al. Cough reflex sensitivity and airway inflammation in patients with chronic cough due to non-acid gastro-oesophageal reflux. Respirology 2011;16:645-52. PUBMED | CROSSREF

57. Ziora D, Jarosz W, Dzielicki J, Ciekielski J, Jacek C, Andrzej K, Szymon D, et al. Citric acid cough threshold in patients with gastroesophageal reflux disease rises after laparoscopic fundoplication. Chest 2005;128:2458-64. PUBMED | CROSSREF

58. Basoglu OK, Pelleg A, Kharitonov SA, Barnes PJ. Contrasting effects of ATP and adenosine on capsaicin challenge in asthmatic patients. Pulm Pharmacol Ther 2017;45:13-8. PUBMED | CROSSREF

59. Kanemitsu Y, Fukumitsu K, Kurokawa R, Takeda N, Suzuki M, Yap J, et al. Increased capsaicin sensitivity in patients with severe asthma is associated with worse clinical outcome. Am J Respir Crit Care Med 2020;201:1068-77. PUBMED | CROSSREF

60. Weinfeld D, Ternesten-Hasséus E, Löwhagen O, Millqvist E. Capsaicin cough sensitivity in allergic asthmatic patients increases during the birch pollen season. Ann Allergy Asthma Immunol 2002;89:419-24. PUBMED | CROSSREF

61. Koskela HO, Hyvärinen L, Brannan JD, Chan HK, Anderson SD. Coughing during mannitol challenge is associated with asthma. Chest 2004;125:1985-92. PUBMED | CROSSREF

62. Purokivi M, Koskela H, Brannan JD, Kontra K. Cough response to isocapnic hyperpnoea of dry air and hypertonic saline are interrelated. Cough 2011;7:8. PUBMED | CROSSREF

https://e-aair.org

https://doi.org/10.4168/aair.2021.13.6.833
67. Koskela HO, Kontra KM, Purokivi MK, Randell JT. Interpretation of cough provoked by airway challenges. Chest 2005;128:3329-35.

68. Purokivi M, Koskela HO, Koistinen T, Magga J, Peuhkurinen K, Kiviniemi V, et al. Utility of cough response during hypertonic histamine challenge in diagnosing asthma. Respir Med 2008;102:1379-84.

69. Purokivi M, Koskela H, Kontra K. Determinants of asthma control and quality of life in stable asthma: evaluation of two new cough provocation tests. Clin Respir J 2013;7:253-60.

70. Cho YS, Lee CK, Yoo B, Moon HB. Cough sensitivity and extrathoracic airway responsiveness to inhaled capsaicin in chronic cough patients. J Korean Med Sci 2002;17:616-20.

71. Pullerits T, Ternesten-Hasséus E, Johansson EL, Millqvist E. Capsaicin cough threshold test in diagnostics. Respir Med 2014;108:1371-6.

72. Holst H, Arendt-Nielsen L, Mosbech H, Vesterhauge S, Elberling J. The capsaicin cough reflex in patients with symptoms elicited by odorous chemicals. Int J Hyg Environ Health 2010;213:66-71.

73. Elberling J, Dirksen A, Johansen JD, Mosbech H. The capsaicin cough reflex in eczema patients with respiratory symptoms elicited by perfume. Contact Dermat 2006;54:158-64.

74. Millqvist E, Ternesten-Hasséus E, Ståhl A, Bende M. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. Environ Health Perspect 2005;113:849-52.

75. Ternesten-Hasséus E, Johansson K, Löwhagen O, Millqvist E. Inhalation method determines outcome of capsaicin inhalation in patients with chronic cough due to sensory hyperreactivity. Pulm Pharmacol Ther 2006;19:172-8.

76. Millqvist E, Johansson A, Bende M. Relationship of airway symptoms from chemicals to capsaicin cough sensitivity in atopic subjects. Clin Exp Allergy 2004;34:619-23.

77. Johansson A, Löwhagen O, Millqvist E, Bende M. Capsaicin inhalation test for identification of sensory hyperreactivity. Respir Med 2002;96:731-5.

78. Millqvist E, Löwhagen O, Bende M. Quality of life and capsaicin sensitivity in patients with sensory airway hyperreactivity. Allergy 2000;55:540-5.

79. Chan K, Ing A, Birring SS. Cough in obstructive sleep apnoea. Pulm Pharmacol Ther 2015;35:129-31.

80. Shi C, Liang S, Xu X, Chen Q, Wang L, Yu L, et al. Cough hypersensitivity in patients with obstructive sleep apnea hypopnea syndrome. Sleep Breath 2019;23:33-9.

81. Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:995-1002.

82. Pecova R, Vrlik M, Tatar M. Cough sensitivity in allergic rhinitis. J Physiol Pharmacol 2005;56 Suppl 4:171-8.

83. Yu L, Xu X, Wang L, Yang Z, Liu H, Qiu Z. Capsaicin-sensitive cough receptors in lower airway are responsible for cough hypersensitivity in patients with upper airway cough syndrome. Med Sci Monit 2013;19:1095-101.

84. Wong CH, Morice AH. Cough threshold in patients with chronic obstructive pulmonary disease. Thorax 1999;54:62-4.

85. Torrego A, Haque RA, Nguyen LT, Hew M, Carr DH, Wilson R, et al. Capsaicin cough sensitivity in bronchiectasis. Thorax 2006;61:706-9.
86. Dicpinigaitis PV. Short- and long-term reproducibility of capsaicin cough challenge testing. Pulm Pharmacol Ther 2003;16:61-5.

87. Field SK, Escalante P, Fisher DA, Ireland B, Irwin RS, Adams TM, et al. Cough due to TB and other chronic infections: CHEST guideline and expert panel report. Chest 2018;153:467-97.

88. Ohkura N, Fujimura M, Nakade Y, Okazaki A, Katayama N. Heightened cough response to bronchoconstriction in cough variant asthma. Respirology 2012;17:964-8.

89. Satia I, Badri H, Woodhead M, O’Byrne PM, Fowler SJ, Smith JA. The interaction between bronchoconstriction and cough in asthma. Thorax 2017;72:1144-6.

90. Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015;385:1198-205.